Formats
  1. Journal Article (66894)
  2. Meeting Abstract (33621)
  3. Book Section (5097)
  4. Review (3749)
  5. Editorial (2165)
  6. Conference Paper (1526)
  7. Correspondence (663)
  8. Guidelines (661)
  9. Research Letter (548)
  10. Book Whole (344)
  11. Miscellaneous (339)
Groups
  1. Department of Medicine (39043)
  2. GSK Faculty (22462)
  3. Solid Tumor Oncology Division (22061)
  4. Surgery (21262)
  5. Survivorship Research (15766)
  6. Sloan Kettering Institute Faculty (15652)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (2139)
  2. 2024 (5384)
  3. 2023 (5806)
  4. 2022 (6169)
  5. 2021 (5714)
  6. 2020 (5618)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4951)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2611)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1814)

More Publications

Publishers
  1. Elsevier Inc. (13846)
  2. American Society of Clinical Oncology (9169)
  3. Springer (7192)
  4. Nature Publishing Group (6375)
  5. American Association for Cancer Research (6014)
  6. Elsevier Science, Inc. (5512)

More Publishers

Results (115607)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world treatment patterns in recurrent or advanced endometrial cancer patients on first-line systemic therapy in the United States
    Meeting Abstract

    Ogando, Y. M.; Chen, L.; Zhang, J.; Kelkar, S. S.; Prabhu, V. S.; Miles, N.; Green, A.; Makker, V.
    Pharmacoepidemiology and Drug Safety (2023)

    Fulltext@MSK | Save
  • Patient selection using genetic alterations associated with radiosensitivity in follicular lymphoma
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Lee, J.; Fregonese, B.; Tringale, K.; Hubbeling, H.; Sarkar, R.; Ma, J.; Seshan, V.; Joffe, E.; more...
    Radiotherapy and Oncology (2023)

    Fulltext@MSK | Save
  • Patterns of failure in 559 primary central nervous system lymphoma patients treated from 1983-2020
    Meeting Abstract

    Tringale, K.; Yahalom, J.; Scordo, M.; Grommes, C.; Imber, B.
    Radiotherapy and Oncology (2023)

    Fulltext@MSK | Save
  • Consolidation patterns and associated outcomes for a large cohort of primary CNS lymphoma patients
    Meeting Abstract

    Imber, B.; Tringale, K.; Scordo, M.; Yahalom, J.; Grommes, C.
    Radiotherapy and Oncology (2023)

    Fulltext@MSK | Save
  • Variations in cumulative dose assessment in re-irradiation scenarios: A multi-centre evaluation
    Meeting Abstract

    Hardcastle, N.; Vasquez Osorio, E.; Mayo, C.; Jackson, A.; Belosi, F.; Chamberlain, M.; Thompson, C.; Palmer, C.; Solomou, N.; Hoffmann, L.; more...
    Radiotherapy and Oncology (2023)

    Fulltext@MSK | Save
  • Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients (Pts) with newly diagnosed multiple myeloma (NDMM): Clinical assessment of key subgroups of the phase 3 MAIA study
    Meeting Abstract

    Moreau, P.; Facon, T.; Usmani, S. Z.; Bahlis, N.; Raje, N.; Plesner, T.; Orlowski, R. Z.; Basu, S.; Nahi, H.; Hulin, C.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Adverse event profiles and time to onset and resolution with tremelimumab ( T) plus durvalumab (D) in patients with unresectable hepatocellular carcinoma (uHCC) in the phase 3 HIMALAYA trial
    Meeting Abstract

    De Toni, E. M.; Sangro, B.; Chan, S. L.; Kudo, M.; Kelley, R. K.; K, K. Y.; Rimassa, L.; Varela, M.; Dayyani, F.; Makowsky, M.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Epidemiological impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) use in previously untreated diffuse large B-cell lymphoma (DLBCL) on second line (2L) treatment: An ad hoc analysis from POLARIX study
    Meeting Abstract

    Oellerich, T.; Boissard, F.; Tilly, H.; Lenz, G.; Collins, G. P.; Pinto, A.; Sehn, L. H.; Salles, G.; Roussel, M.; Simonella, L.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Primary overall survival (OS) analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in relapsed/refractory large B-cell lymphoma (R/R LBCL)
    Meeting Abstract

    Dreger, P.; Westin, J.; Oluwole, O.; Kersten, M. J.; Miklos, D.; Perales, M. A.; Ghobadi, A.; Rapoport, A.; Sureda, A.; Jacobson, C.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Subgroup analyses of primary refractory vs early relapsed large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy
    Meeting Abstract

    Glass, B.; Nastoupil, L.; Kamdar, M.; Chavez, J. C.; Ghesquieres, H.; Ghosh, M.; Holmes, H.; López-Guillermo, A.; Martínez-López, J.; Novak, U.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save